Skip to content
Briefings are running a touch slower this week while we rebuild the foundations.See roadmap
Pandemics and Biosecurity
9JUN

FAO costs drug-resistance inaction at $318bn

2 min read
09:58UTC

The FAO put a price on antimicrobial resistance on 3 June, projecting $318bn in cumulative livestock losses by 2040, about six times the cost of acting now.

ScienceDeveloping
Key takeaway

Pricing drug resistance as $318bn in lost production reaches ministries a death toll never moved.

The Food and Agriculture Organization (FAO), the UN's Rome-based agency for food and farming, put a price on inaction over AMR (antimicrobial resistance, the process by which bacteria stop responding to the drugs meant to kill them) on 3 June. Its report projects global antimicrobial use in livestock rising 30% by 2040 against a 2019 baseline, and cumulative livestock production losses reaching $318bn by 2040 under a high-resistance scenario 1. That $318bn runs about six times the cost of acting now.

May's adoption of the WHO Global Action Plan on AMR set a mortality target, a 10% cut in bacterial AMR deaths by 2030. FAO has now attached a balance-sheet figure to the alternative, routing the same problem through food-security economics to reach an audience that a death toll did not. The 6:1 inaction-to-action ratio is the lever, reframing mitigation spending as loss avoidance rather than public-health cost.

Cheap antibiotics keep crowded herds productive, so use climbs with demand for meat, and resistance follows the use, an unremarkable chain that the $318bn figure now prices. Pricing the loss in production rather than deaths is how the issue reaches the agriculture and finance ministries that control the antibiotics and that a public-health framing never reached.

Deep Analysis

In plain English

Farmers use antibiotics to keep livestock healthy and speed up animal growth. When antibiotics are used too frequently, bacteria evolve to resist them, making those drugs less effective for both animals and humans over time. This is called antimicrobial resistance, or AMR. FAO, the UN's food and agriculture body, published a report on 3 June estimating that unchecked AMR will cost the farming industry $318 billion in lost livestock production by 2040, as animals die from infections that should be treatable. Preventing that outcome would cost around one-sixth as much. The report argues that tackling antibiotic overuse in farming serves both economic and public health goals.

Deep Analysis
Root Causes

The projected 30% rise in livestock antimicrobial use to 2040 reflects a structural dependency: antibiotic prophylaxis compensates for suboptimal biosecurity in intensive production systems. The economic incentive structure rewards volume and speed of production over herd health investment, particularly in markets where veterinary drug regulation is weak or enforcement is absent.

The WHO GAP-AMR 2026-2036 , adopted 23 May, sets a 10% reduction target in AMR-attributable deaths by 2030 , a human-health metric. The FAO report reframes AMR as a food-security and economic threat independent of that metric, addressing a different political constituency: agriculture ministries and development finance institutions that do not engage with WHO's public-health framing.

What could happen next?
  • Consequence

    FAO's $318bn figure provides an economic mandate for agriculture ministries to engage with the WHO GAP-AMR 2026-2036 (ID:3599) framework , translating a public-health target into a production-economics argument that reaches beyond health ministry budgets.

  • Risk

    The 30% projected rise in livestock antimicrobial use by 2040 is concentrated in regions with limited veterinary drug regulatory capacity, meaning the economic cost will fall disproportionately on small-scale farmers in lower-income countries who have the least ability to absorb it.

Sources:FAO
First Reported In

Update #6 · Ebola outbreak gets an R0, and a fork

FAO· 9 Jun 2026
Read original
Causes and effects
This Event
FAO costs drug-resistance inaction at $318bn
Pricing AMR as lost production rather than deaths is how the issue reaches the agriculture and finance ministries that a mortality figure never moved.
Different Perspectives
World Health Organization
World Health Organization
WHO's DON606 recalibration to confirmed-only reporting gives the clean baseline the CDC model rests on, but the apparent fall from 1,040 to 534 carries misinterpretation risk WHO communications have not pre-empted. The PABS deadlock ahead of IGWG7 and continuing MBP134/remdesivir assessment without authorisation make WHO the body most able to accelerate the two decisions that could change the outbreak's trajectory.
European Union (ECDC)
European Union (ECDC)
ECDC's Week 23 CDTR tracked four simultaneous non-Ebola signals: the Dermatophilus congolensis novel-transmission cluster across France, Germany and Spain; a 4.2-fold malaria surge in Mayotte; the Salmonella ST2045 multi-country cluster; and two new Saudi MERS cases. The continental early-warning layer is carrying a full multi-pathogen picture while Bundibugyo dominates headlines.
Uganda
Uganda
Uganda's 19 confirmed cases are concentrated in Kampala and Wakiso, an urban cluster that applied the 2022 Sudan-ebolavirus playbook; the Bwera border laboratory shortens cross-border confirmation to same-day. Uganda's regulatory authority must co-sign before MBP134 or remdesivir can dose any patient.
Democratic Republic of the Congo
Democratic Republic of the Congo
Kinshasa shares Bundibugyo sequence data in real time with no treaty-guaranteed access to the vaccines that data informs, and its health minister called the US entry ban discriminatory while negotiating an early lift. DRC accounts for 515 of 534 confirmed cases and faces IS-controlled access blockades in Mambasa that health authorities cannot resolve.
United States (HHS/CDC)
United States (HHS/CDC)
HHS expanded the Ebola entry ban to green-card holders on 5 June, widening a restriction expiring around 17 June against WHO advice. The CDC simultaneously published the R0=2.51 modelling, the sharpest analytical contribution to the response, from a federal bench that holds the NIH and acting CDC director roles in one person.
Imperial College London / Cori and Ferguson
Imperial College London / Cori and Ferguson
Anne Cori and Neil Ferguson place the case-fatality ratio at 30 to 40 per cent and read the 6.8-to-1 suspected-to-confirmed ratio as evidence that the laboratory figure understates true lethality. Many people die before a swab reaches them.